Amalia Levy

Amalia Levy

Auto-generated profile, based on publicly available information

Amalia Levy

Affiliation Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BFBoris Fishman
Boris Fishman
SDSharon Daniel
Sharon Daniel
GKGideon Koren
Gideon Koren
ELEitan Lunenfeld
Eitan Lunenfeld
ALAmalia Levy
Amalia Levy
Opioids constitute a cornerstone of pain relief treatment. However, opioid safety during pregnancy has not been well established. Recent studies reported an association between in utero opioid exposure and spina bifida. In order to further evaluate the association of opioids exposure during pregnancy with adverse pregnancy outcomes, we conducted a large historical cohort by linking four databases: medications dispensations, births, pregnancy terminations for medical reasons and infant hospitalizations during the years of 1999–2009. Confounders that were controlled for included maternal age, ethnicity, maternal diabetes, smoking status, parity, obesity, year and folic acid intake. A secondary analysis for total major malformations and for spina bifida was performed using propensity score matching for first trimester exposure. Of the 101,586 women included in the study, 3003 were dispensed opioids during the first trimester. Intrauterine exposure to opioids was not associated with overall major malformations (adjusted odds ratio (aOR) 0.97, 95% CI 0.83–1.13), cardiovascular malformations (aOR = 0.89, 95% CI 0.70–1.13) other malformations by systems or spina bifida in particular. However, the risk for spina bifida among newborns and abortuses who were exposed to codeine was four times higher than that of the unexposed (aOR = 4.42, 95% CI 1.60–12.23). This association remained significant in a secondary analysis using propensity score matching. Third trimester exposure to opioids was not associated with low birth weight (aOR = 1.08, 95% CI 0.77–1.52), perinatal death (aOR = 1.38, 95% CI 0.64–2.99) and other adverse pregnancy outcomes. These findings suggest that opioids exposure (as a homogenous group) is not a significant risk factor for overall major malformations. Exposure to codeine during the first trimester was found to be associated with increased risk of spina bifida. However, this finding was based on a small number of cases and need to be verified in future work.

14 May 2026 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AHAriel Avraham Hasidim
Ariel Avraham Hasidim
ISItamar Ben Shitrit
Itamar Ben Shitrit
DIDaphna Idan
Daphna Idan
TMTal Michael
Tal Michael
ALAmalia Levy
Amalia Levy
SDSharon Daniel
Sharon Daniel
Background: Pain and fever are common in early pregnancy, yet their management poses a major clinical dilemma. Although not confirmed, recent studies have raised safety concerns regarding acetaminophen. Evidence on the use of nonsteroidal anti-inflammatory drugs (NSAID) in the first trimester remains inconclusive. This uncertainty has left clinicians with limited evidence to guide treatment decisions. This study evaluated the association between first-trimester NSAID exposure and the risk of major congenital malformations (MCMs) in a large, population-based cohort of pregnancies. Methods and findings: We conducted a population-based retrospective cohort study within the Southern Israeli Pregnancy Registry (siPREG) project, including all singleton pregnancies of women aged 15–45 years resulting in live births, stillbirths, or elective terminations for fetal malformations at a Soroka University Medical Center between 1998 and 2018. Pregnancies exposed to established teratogens, multiple gestations, and those with documented genetic or chromosomal anomalies were excluded. First-trimester NSAID exposure was defined by pharmacy dispensations (overall and by specific agents). MCMs were identified from linked clinical, hospitalization, and termination records through the first postnatal year. Propensity scores were estimated using covariates selected via a directed acyclic graph, including maternal age, ethnicity, diabetes, medical indication for NSAID use, exposure to other antipyretics, obesity, smoking, folic-acid use, gravidity, perinatal care, and year of pregnancy. Generalized full matching was used to balance covariates. Adjusted risk ratios were derived using weighted Poisson regression with G-computation, and two-way cluster-robust standard errors, jointly clustering by maternal identifier and matching subclass. Sensitivity analyses included a dose–response assessment across defined-daily-dose (DDD) categories and a tipping-point analysis evaluating the impact of potential misclassification from unrecorded over-the-counter NSAID use. A total of 264,858 singleton pregnancies were included in the final cohort; 20,202 (7.6%) were exposed to NSAID, most commonly ibuprofen (5.1%), diclofenac (1.6%), and naproxen (1.2%). NSAID exposure, in total and as individual agents, was not associated with MCMs overall (8.2% versus 7.0%; matched-adjusted-Relative Risk (aRR) = 0.99 (95% CI [0.90,1.10])) or with organ-system-specific MCMs, including cardiovascular (matched-aRR = 1.05 (95% CI [0.92,1.20]), musculoskeletal (matched-aRR = 1.03 (95% CI [0.77,1.39])), central nervous system (matched-aRR = 0.77 (95% CI [0.53,1.11])), cleft palate (matched-aRR = 0.95 (95% CI [0.47–1.91])), gastrointestinal (matched-aRR = 1.03 (95% CI [0.64–1.63])), and genitourinary (matched-aRR = 0.99 (95% CI [0.72,1.35])) malformations. Dose–response analyses showed no significant association with MCMs across cumulative NSAID exposure: short-term (1–7 DDD, matched-aRR = 1.06 (95% CI [0.97,1.15]), medium-term (8–21 DDD, matched-aRR = 1.10 (95% CI [0.99,1.22]), and long-term (>21 DDD, matched-aRR = 1.24 (95% CI [0.94,1.63])). The main limitation was the potential for minor exposure misclassification due to over-the-counter availability of ibuprofen, although sensitivity analyses simulating such misclassification suggested minimal impact on the risk estimates. Conclusion: In this large, population-based cohort, we found no evidence supporting an association between first-trimester exposure to NSAID and MCMs, providing reassuring evidence regarding their fetal safety in early pregnancy.

29 April 2026 in Human Reproduction Open
Verified
Journal Article
Open access
DIDaphna Idan
Daphna Idan
AHAriel Avraham Hasidim
Ariel Avraham Hasidim
ISItamar Ben Shitrit
Itamar Ben Shitrit
TMTal Michael
Tal Michael
ALAmalia Levy
Amalia Levy
SDSharon Daniel
Sharon Daniel
STUDY QUESTION: Is maternal paracetamol exposure during the first and third trimesters of pregnancy associated with major congenital malformations and adverse perinatal and postnatal outcomes? SUMMARY ANSWER: Maternal paracetamol use during the first or third trimester was not associated with major congenital malformations or adverse perinatal and postnatal outcomes. WHAT IS KNOWN ALREADY: Paracetamol is the most commonly used analgesic and antipyretic during pregnancy and has long been considered safe. However, recent concerns have been raised regarding potential fetal and perinatal risks, with inconsistent findings across studies. STUDY DESIGN, SIZE, DURATION: In this population-based retrospective study, the cohort included 265 143 singleton pregnancies resulting in delivery or elective termination at a single tertiary medical center between 1998 and 2018. Separate analytic cohorts comprised 264 858 pregnancies for first-trimester analyses and 257 285 pregnancies for third-trimester analyses. Follow-up extended through delivery and the first year of life for congenital malformation ascertainment. There was no loss to follow-up for primary outcomes due to complete registry linkage. PARTICIPANTS/MATERIALS, SETTING, METHODS: All singleton pregnancies among women aged 15–45 years, insured by a regional health maintenance organization and managed at a tertiary university medical center, were included. Pregnancies with chromosomal or genetic abnormalities, teratogenic drug exposure, or multiple gestations were excluded. Paracetamol exposure (prescription and over-the-counter dispensations) was assessed separately for the first trimester (≤13 weeks) and third trimester (≥27 weeks) and categorized by total defined daily doses. Exposed and unexposed pregnancies were compared using multivariable Poisson regression and propensity score-based generalized full matching. Matching incorporated maternal demographics, comorbidities, pregnancy characteristics, and indications for paracetamol use. After matching, covariate balance was achieved (standardized mean differences <0.1 for all variables). MAIN RESULTS AND THE ROLE OF CHANCE: During the first trimester, paracetamol exposure was recorded in 41 011 pregnancies (15.5%); major congenital malformations occurred in 7.9% of exposed versus 6.9% of unexposed pregnancies (crude RR 1.14; 95% CI, 1.1–1.18), with no association after matching (adjusted RR 1.04; 95% CI, 0.98–1.10) and no associations with organ-specific malformations. Third-trimester exposure was recorded in 36 375 pregnancies (14.1%) and was not associated, in the matched analyses, with preterm birth, low or very low birth weight, perinatal death, low Apgar scores, or markers of premature ductus arteriosus closure or neonatal renal impairment. Dose–response and sensitivity analyses showed no evidence of increased risk, and the results were robust to plausible levels of exposure misclassification. LIMITATIONS, REASONS FOR CAUTION: Paracetamol exposure was based on dispensation rather than confirmed intake, and miscarriages were not captured. Exposure misclassification due to unrecorded over-the-counter use is possible; however, sensitivity analyses suggest it is unlikely to materially affect the findings. WIDER IMPLICATIONS OF THE FINDINGS: These findings are consistent with large cohort studies and contribute to the evidence supporting the relative safety of paracetamol use during early and late pregnancy. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for this study. All authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

6 August 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
ISItamar Ben Shitrit
Itamar Ben Shitrit
DIDaphna Idan
Daphna Idan
AHAriel Avraham Hasidim
Ariel Avraham Hasidim
TMTal Michael
Tal Michael
ALAmalia Levy
Amalia Levy
SDSharon Daniel
Sharon Daniel
Pain and fever are common in pregnancy. Dipyrone is widely used in Europe, Latin America, and parts of Asia, but is banned in other countries due to concerns about agranulocytosis. Evidence on its safety in pregnancy remains limited and inconsistent. This study aimed to evaluate whether maternal dipyrone use during the first‐ and third‐trimesters is associated with major congenital malformations (MCMs) and adverse perinatal or early neonatal outcomes. A population‐based cohort of all pregnancies that delivered or underwent elective termination at Soroka University Medical Center from 1998 to 2018, linking maternal, neonatal, and termination records with pharmacy dispensations. Generalized full matching and Poisson regression were used to study the association of first‐and third‐trimester dipyrone exposure and risks of MCMs, perinatal outcomes, and early neonatal complications, including preterm ductal closure and renal injury. Among 264,858 singleton pregnancies analyzed for first‐trimester exposure, 8,987 (3.4%) were exposed to Dipyrone. MCMs occurred in 8.0% of exposed vs. 7.0% of unexposed; however, no association was found after matching (adjusted risk ratio (RR) 1.04, 95% CI: 0.88–1.22). No associations were observed with malformation in other organ systems. In third‐trimester analyses ( n = 257,285; 6,362 (2.5%) exposed), dipyrone was not associated with preterm birth, low birthweight, perinatal death, low Apgar scores, or evidence of renal toxicity or premature ductus arteriosus constriction. No dose–response was observed. Sensitivity Analysis for over‐the‐counter use indicated minimal possible misclassification bias. This study provides evidence supporting maternal dipyrone use in early or late pregnancy is not associated with MCMs, adverse perinatal outcomes, or early neonatal complications.